Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,961.30 | 46.50 | 0.52% |
| CAC 40 | 8,326.62 | 73.96 | 0.90% |
| DAX 40 | 25,118.27 | 220.82 | 0.89% |
| Dow JONES (US) | 52,487.41 | 139.02 | 0.27% |
| FTSE 100 | 10,472.45 | 16.59 | -0.16% |
| HKSE | 24,030.18 | 169.28 | -0.70% |
| NASDAQ | 26,206.89 | 336.24 | 1.30% |
| Nikkei 225 | 67,743.85 | 924.80 | 1.38% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,543.64 | 60.93 | 0.81% |
| S&P/ASX 200 | 8,762.50 | 44.40 | 0.51% |
| SSE Composite Index | 4,036.59 | 65.71 | 1.65% |